within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AB38_AndexanetAlfa;

model AndexanetAlfa
  extends Pharmacolibrary.Drugs.ATC.V.V03AB38;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V03AB38</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Andexanet alfa is a recombinant modified human factor Xa decoy protein used to reverse the anticoagulant effects of direct and indirect factor Xa inhibitors, such as apixaban and rivaroxaban, in cases of life-threatening or uncontrolled bleeding. It is approved for use in adults by the FDA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model described for healthy adult volunteers following intravenous bolus followed by continuous infusion.</p><h4>References</h4><ol><li><p>Heo, YA (2018). Andexanet Alfa: First Global Approval. <i>Drugs</i> 78(10) 1049–1055. DOI:<a href=\"https://doi.org/10.1007/s40265-018-0940-4\">10.1007/s40265-018-0940-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29926311/\">https://pubmed.ncbi.nlm.nih.gov/29926311</a></p></li><li><p>Lu, G, et al., &amp; Conley, PB (2017). Preclinical safety and efficacy of andexanet alfa in animal models. <i>Journal of thrombosis and haemostasis : JTH</i> 15(9) 1747–1756. DOI:<a href=\"https://doi.org/10.1111/jth.13768\">10.1111/jth.13768</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28682477/\">https://pubmed.ncbi.nlm.nih.gov/28682477</a></p></li><li><p>Hu, TY, et al., &amp; Asirvatham, SJ (2016). Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. <i>Vascular health and risk management</i> 12 35–44. DOI:<a href=\"https://doi.org/10.2147/VHRM.S89130\">10.2147/VHRM.S89130</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26937198/\">https://pubmed.ncbi.nlm.nih.gov/26937198</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AndexanetAlfa;
